Clinical Study of Irinotecan Liposome (II)-Based Combination Treatment for Irinotecan-resistant Colorectal Cancer.

This study is testing a new form of the chemotherapy drug irinotecan (a liposomal version — wrapped in tiny fat particles to improve delivery) combined with other treatments for colorectal cancer that has stopped responding to standard irinotecan-based therapy. The goal is to see if this reformulated drug can overcome resistance. **You may be eligible if...** - You are 18 or older with colorectal cancer - Your cancer progressed during or after treatment that included standard irinotecan - You have measurable cancer on imaging - Your overall health and organ function are adequate - You have not had more than a specified number of prior treatment lines **You may NOT be eligible if...** - You have active brain metastases - You have significant heart, liver, or kidney problems - You have uncontrolled infections or bleeding disorders - You are pregnant or breastfeeding - You have had certain prior cancer treatments that overlap with study drugs Talk to your doctor to see if this trial is right for you.